News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
309,933 Results
Type
Article (14268)
Company Profile (109)
Press Release (295556)
Section
Business (99339)
Career Advice (570)
Deals (20505)
Drug Delivery (67)
Drug Development (39968)
Employer Resources (49)
FDA (6992)
Job Trends (7170)
News (171114)
Policy (15526)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (8)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (505)
Adcomms (6)
Allergies (33)
Alliances (26446)
ALS (43)
Alzheimer's disease (477)
Antibody-drug conjugate (ADC) (38)
Approvals (7035)
Artificial intelligence (105)
Autoimmune disease (7)
Automation (3)
Bankruptcy (189)
Best Places to Work (5269)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (46)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (88)
Cancer (699)
Cardiovascular disease (71)
Career advice (499)
Career pathing (11)
CAR-T (23)
Cell therapy (98)
Cervical cancer (4)
Clinical research (33628)
Collaboration (348)
Compensation (146)
Complete response letters (17)
COVID-19 (810)
CRISPR (19)
C-suite (115)
Cystic fibrosis (41)
Data (722)
Denatured (15)
Depression (12)
Diabetes (92)
Diagnostics (1894)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (58)
Drug pricing (65)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (36278)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (44040)
Executive appointments (379)
FDA (7446)
Featured Employer (22)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (256)
Gene editing (38)
Generative AI (8)
Gene therapy (103)
GLP-1 (348)
Government (1405)
Grass and pollen (2)
Guidances (17)
Healthcare (5073)
Huntington's disease (4)
IgA nephropathy (9)
Immunology and inflammation (35)
Indications (13)
Infectious disease (849)
Inflammatory bowel disease (63)
Inflation Reduction Act (6)
Influenza (16)
Intellectual property (48)
Interviews (77)
IPO (9190)
IRA (29)
Job creations (2149)
Job search strategy (448)
Kidney cancer (6)
Labor market (10)
Layoffs (178)
Leadership (3)
Legal (3949)
Liver cancer (19)
Lung cancer (99)
Lymphoma (55)
Machine learning (1)
Management (16)
Manufacturing (149)
MASH (34)
Medical device (2933)
Medtech (2935)
Mergers & acquisitions (11667)
Metabolic disorders (267)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (662)
NextGen: Class of 2025 (2220)
Non-profit (723)
Northern California (818)
Now hiring (7)
Obesity (145)
Opinion (120)
Ovarian cancer (26)
Pain (55)
Pancreatic cancer (27)
Parkinson's disease (49)
Partnered (10)
Patents (118)
Patient recruitment (33)
Peanut (11)
People (31767)
Pharmaceutical (64)
Pharmacy benefit managers (12)
Phase I (9050)
Phase II (14454)
Phase III (12420)
Pipeline (442)
Podcasts (46)
Policy (59)
Postmarket research (1427)
Preclinical (3627)
Press Release (26)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (138)
Rare diseases (167)
Real estate (2943)
Recruiting (17)
Regulatory (11032)
Reports (16)
Research institute (650)
Resumes & cover letters (67)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (40)
Series B (17)
Service/supplier (3)
Sickle cell disease (35)
Southern California (875)
Special edition (6)
Spinal muscular atrophy (78)
Sponsored (6)
Startups (1885)
State (2)
Stomach cancer (3)
Supply chain (30)
The Weekly (28)
United States (8622)
Vaccines (167)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (33)
Last 7 days (255)
Last 30 days (1064)
Last 365 days (14654)
2025 (3425)
2024 (15349)
2023 (17676)
2022 (23559)
2021 (24856)
2020 (23765)
2019 (18185)
2018 (14264)
2017 (16086)
2016 (14953)
2015 (18006)
2014 (14142)
2013 (11993)
2012 (12940)
2011 (13195)
2010 (12114)
Location
Africa (317)
Alabama (15)
Alaska (1)
Arizona (73)
Arkansas (3)
Asia (22067)
Australia (2878)
California (2059)
Canada (948)
China (249)
Colorado (76)
Connecticut (98)
Delaware (60)
Europe (41936)
Florida (388)
Georgia (50)
Idaho (14)
Illinois (209)
India (14)
Indiana (146)
Iowa (1)
Japan (90)
Kansas (60)
Kentucky (13)
Maine (35)
Maryland (300)
Massachusetts (1664)
Michigan (84)
Minnesota (110)
Mississippi (2)
Missouri (24)
Montana (10)
Nebraska (8)
Nevada (29)
New Hampshire (11)
New Jersey (829)
New Mexico (8)
New York (659)
North Carolina (513)
North Dakota (2)
Northern California (818)
Ohio (62)
Oklahoma (4)
Oregon (18)
Pennsylvania (519)
Puerto Rico (8)
Rhode Island (10)
South America (533)
South Carolina (7)
Southern California (875)
Tennessee (43)
Texas (309)
Utah (64)
Virginia (73)
Washington D.C. (29)
Washington State (146)
West Virginia (1)
Wisconsin (21)
309,933 Results for "sermonix pharmaceuticals llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
March 24, 2025
·
5 min read
BioMidwest
Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene
Sermonix Pharmaceuticals Inc. today announced that China’s National Medical Products Administration (NMPA) approved the investigational new drug application (IND) for oral lasofoxifene (HLX78 in China) submitted with the assistance of Chinese development partner Shanghai Henlius Biotech, Inc. (2696.HK).
June 6, 2024
·
6 min read
BioMidwest
Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024
Sermonix Pharmaceuticals Inc. today announced it will present a poster updating the progress of its Phase 3 ELAINE-3 clinical trial at the annual meeting of the American Society of Clinical Oncology (ASCO). ASCO 2024 will be held May 31-June 4, 2024, at McCormick Place in Chicago.
May 30, 2024
·
2 min read
Business
Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website
Sermonix Pharmaceuticals Inc. today announced it is now an industry member of the Metastatic Breast Cancer Alliance, a collective of cancer nonprofits, pharmaceutical and biotech industry members and individual patient advocates working collaboratively to transform and improve the lives of people living with mBC.
February 12, 2024
·
3 min read
BioMidwest
Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s Effects on Vaginal Atrophy in Postmenopausal Women
Sermonix Pharmaceuticals Inc. announced that an article on the effects of its lead investigational drug, oral lasofoxifene, on moderate to severe vaginal atrophy in postmenopausal women was published April 23, 2024 in Menopause: The Journal of The Menopause Society.
April 29, 2024
·
3 min read
BioMidwest
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), today announced the publication of its scholarly article, “Lasofoxifene as a Potential Treatment for Aromatase Inhibitor-Resistant ER-Positive Breast Cancer,” in the peer-reviewed journal Breast Cancer Research.
June 10, 2024
·
5 min read
Business
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. (2696.HK), today announced a strategic collaboration agreement in which Henlius will receive exclusive rights to develop, manufacture and commercialize Sermonix’s lead investigational drug, lasofoxifene, in China.
January 10, 2024
·
9 min read
BioMidwest
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, broadly shared the three poster presentations examining clinical data tied to Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations studies.
December 12, 2023
·
4 min read
BioMidwest
Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024
Sermonix Pharmaceuticals Inc. today announced it will host a virtual KOL fireside chat on Monday, April 22, 2024 from noon to 1 p.m. ET, featuring Senthil Damodaran, M.D., Ph.D. (MD Anderson Cancer Center) and Seth Wander, M.D., Ph.D. (Harvard Medical School, Massachusetts General Hospital) to discuss the unmet need and current treatment landscape for metastatic breast cancer.
April 19, 2024
·
4 min read
BioMidwest
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
Sermonix Pharmaceuticals Inc. today announced that results of its two Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies were published in Annals of Oncology, the peer-reviewed journal of the European Society for Medical Oncology (ESMO) and the Japanese Society of Medical Oncology.
December 11, 2023
·
6 min read
1 of 30,994
Next